Tenaya Therapeutics Inc (OQ:TNYA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 171 Oyster Point Blvd., Suite 500
Tel: N/A
Website: https://www.tenayatherapeutics.com
IR: See website
Key People
Faraz Ali
Chief Executive Officer, Director
Leone D. Patterson
Chief Financial and Business Officer
Timothy Hoey
Chief Scientific Officer
Whittemore Tingley
Chief Medical Officer
Business Overview
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of disease-modifying therapies that includes both gene therapies and small molecules discovered internally and developed using its product platforms and core capabilities to target defined sub-populations of patients with rare or prevalent forms of heart disease. Its product platforms include Gene Therapy, Cellular Regeneration and Precision Medicine to discover novel therapies for various forms of heart disease. The Company's lead product candidates include, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy, TN-301, a small molecule for heart failure with preserved ejection fraction, and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Financial Overview
For the nine months ended 30 September 2023, Tenaya Therapeutics Inc revenues was not reported. Net loss increased 4% to $94.1M. Higher net loss reflects Research and development - Balancing v increase of 8% to $70M (expense), Stock-based Compensation in SGA increase of 37% to $6.2M (expense), Stock-based Compensation in R&D increase of 38% to $5.2M (expense).
Employees: 141 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $6.30M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$125.65M as of Sep 30, 2023
Net annual income (TTM): -$127.67M as of Sep 30, 2023
Free cash flow (TTM): -$104.47M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 68,111,019 as of Nov 2, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.